Other Medical Supplies

Guangdong Lechen Sanitary Products Co., Ltd. – Disposable Medical Underpad Undersheet Cover Pad Our Disposable Medical Underpads are specially designed for nursing adults, elderly care, hospitals, and patient protection. With high absorbency and waterproof protection, these underpads help keep beds, wheelchairs, and furniture clean, dry, and hygienic. Key Features: High Absorbency Core: Quickly absorbs and locks in liquid to keep the surface dry and comfortable. Waterproof Back Sheet: Prevents leakage and protects mattresses, beds, and furniture. Soft & Skin-Friendly: Gentle non-woven top layer reduces irritation and provides comfort for long-term use. Leak-Proof Protection: Designed for reliable day and night protection. Disposable & Hygienic: Easy to replace and dispose of, improving convenience and cleanliness. Multi-Purpose Use: Suitable for hospitals, nursing homes, home care, wheelchairs, and patient beds. OEM & ODM Service: Customized sizes, absorbency, packaging, and branding available. Common Concerns: How absorbent are the underpads? The super absorbent core effectively locks in moisture and prevents leakage. Can they be used overnight? Yes, designed for both daytime and overnight protection. Are they suitable for sensitive skin? Yes, soft breathable materials help reduce skin irritation. Can they protect beds and furniture? Absolutely, the waterproof backing prevents liquid penetration. Are different sizes available? Yes, multiple sizes and custom specifications are available. For inquiries, free samples, or bulk orders, please contact us: Edward Lu Email: edwardlechen@outlook.com Whatsapp/WeChat: +8615521177028 Factory Address: Block 2, No. 10 Jujin Road, Baini Town, Sanshui District, Foshan City, Guangdong Guangdong Lechen Sanitary Products Co., Ltd.

Minimum Order: 10000

Infusion chair,Infusion waiting chair,waiting-room bench,Medical chair,Hospital chair,chair,Hospital infusion chair Material: stainless steel or other materials Drive by other person Aldult or Child type are available It can make according to your requirement,drawing or sample. If any demand,welcome to contact us freely.

Minimum Order: 1 bags

medical small cart, medical cart, small cart, stainless steel cart, aluminum alloy cart, warehouse cart,medical small pull car, Material; stainless steel or other materials Folding type Load capacity: 100kgs It can make according to your requirement,drawing and sample. If any demand, welcome to contact us freely.

Minimum Order: 1 bags

Hospital trolley, nursing cart, medical treatment car, therapeutic instrument car, nurse cart, medical record cart, trolley, therapeutic equipment cart, small medicine cart, Materials: stainless steel and other materials It can make according to your requirement,drawing or sample. If any demand,welcome to contact us freely. Specification: 860x455x900mm

Minimum Order: 1 bags

In the dynamic landscape of pharmaceuticals and biopharmaceuticals, the role of FDA-approved Contract Development and Manufacturing Organizations (CDMOs) has become increasingly significant. These specialized partners facilitate the complex journey from drug development to manufacturing, embodying a blend of expertise, experience, and authority that is crucial for ensuring compliance with rigorous regulatory standards. FDA-approved CDMOs possess a deep understanding of the stringent requirements set forth by the Food and Drug Administration. Their approval signifies not only adherence to Good Manufacturing Practices (GMP) but also a commitment to quality and safety in the production of pharmaceutical products. Such organizations are equipped with advanced technologies and processes designed to streamline development and manufacturing, minimizing time to market while optimizing product efficacy. The expertise of an FDA-approved CDMO extends beyond manufacturing capabilities; it encompasses a wide array of services, including formulation development, process optimization, and analytical testing. These organizations often employ teams of highly skilled scientists and engineers whose backgrounds include decades of experience in the pharmaceutical industry. This seasoned expertise allows CDMOs to tackle complex challenges and navigate the multifaceted regulatory landscape, ensuring seamless integration and compliance with evolving standards. Experience is a critical component that sets FDA-approved CDMOs apart. Many have established long-standing partnerships with both emerging biotech firms and large pharmaceutical companies, providing tailored solutions that address unique project needs. Their extensive portfolios often include a range of therapeutic areas, showcasing a track record of successful product launches and regulatory approvals. Such experience imbues CDMOs with the knowledge necessary to anticipate potential pitfalls and optimize processes, thereby enhancing overall project outcomes. Authoritativeness is further underscored by FDA-approved CDMOs’ commitment to innovation and continuous improvement. Their investments in cutting-edge technology and adherence to industry best practices bolster their reputation as reliable partners within the pharmaceutical ecosystem. Additionally, many are actively engaged in research and development initiatives, contributing to advancements in drug delivery systems and manufacturing techniques. Ultimately, an FDA- approved CDMO partner serves as a vital extension of a pharmaceutical company’s capabilities, bridging the gap between concept and commercialization. By leveraging their expertise, experience, and established authority, these organizations play an indispensable role in bringing high- quality therapeutics to market, while ensuring compliance with the highest standards of safety and efficacy. In a sector where the stakes are enormous, the partnership with an FDA-approved CDMO can significantly enhance the likelihood of success.

Oral Solid Dosage Formulation Development Understanding Oral Solid Dosage Formulation Development Oral Solid Dosage Formulation (OSDF) development is a critical field within pharmaceutical sciences, focusing on the creation of dosage forms such as tablets and capsules that are designed to deliver medications effectively and safely. This process involves several key components and sophisticated mechanisms, all aimed at ensuring that the final product meets therapeutic requirements and patient preferences. The OSDF process begins with the selection of active pharmaceutical ingredients (APIs), which are the biologically active components that produce the desired therapeutic effect. Once the APIs are chosen, excipients, or inactive substances, are selected to aid in the formulation. These excipients can enhance stability, bioavailability, and palatability, and they play a significant role in the tablet's compressibility and disintegration properties. After formulating a prototype, the next step involves evaluating the physical and chemical properties of the formulation. Technologies such as high shear mixing, fluidized bed drying, and roller compaction are pivotal in creating homogeneous mixtures of powders, which are essential for consistent quality and performance. For instance, fluidized bed technology enables efficient drying and granulation processes, leading to improved flowability of powders that subsequently enhances tableting operations. In recent years, advancements in technology have revolutionized OSDF development. Continuous manufacturing, for example, allows for real-time monitoring and adjustment of production parameters, ensuring consistent product quality while reducing manufacturing time and costs. This is achieved through advanced process analytical technology (PAT), which includes tools such as spectroscopy and chromatography to monitor the quality of the product at various stages of production. A practical example of advanced technology application can be observed in the development of extended-release tablets. By employing matrix systems that utilize hydrophilic and hydrophobic excipients, formulation scientists can control the release rate of the API over an extended period, thereby enhancing therapeutic efficacy and patient adherence. In conclusion, the development of Oral Solid Dosage Forms is a multifaceted process that marries traditional formulation science with modern technological innovations. As the industry continues to evolve, the importance of advanced technologies becomes ever more crucial in facilitating efficient production processes while ensuring the highest standards of quality. For those interested in learning more about OSDF development or seeking reliable suppliers in this field, please contact us for further information.

Gene Therapy Viral Vector Manufacturing **Product Description: Gene Therapy Viral Vector Manufacturing** Unlock the future of healthcare with our cutting-edge Gene Therapy Viral Vector Manufacturing services. At [Your Company Name], we specialize in creating high- quality viral vectors tailored to support your unique gene therapy solutions. Our state-of-the-art facilities and advanced techniques are designed to meet the rigorous demands of modern therapeutics, ensuring that your innovative treatments are both effective and reliable. **Key Selling Point:** What sets us apart is our unparalleled commitment to quality and precision. We utilize a streamlined manufacturing process that combines rigorous quality control with scalable production capabilities. This ensures that you receive not only the highest-grade viral vectors, but also the flexibility to meet your project’s specific needs, no matter the scale. From preclinical to clinical trials, our tailored solutions empower your research and accelerate your path to market. Let us be your trusted partner in this groundbreaking field. With our Gene Therapy Viral Vector Manufacturing, you can focus on what matters most— transforming lives through innovative therapies. Contact us today to learn how we can help you turn your vision into reality.

**Company Introduction:** Welcome to Lianhe Aigen Pharma Co., Ltd, a leading provider of ADC CDMO Services committed to advancing the field of targeted therapeutics. At [Your Company Name], we specialize in the development and manufacturing of Antibody-Drug Conjugates (ADCs), leveraging our extensive expertise to support pharmaceutical and biotech companies in their quest for innovative cancer treatments. Our comprehensive ADC CDMO Services encompass every stage of the product lifecycle, including: 1. **Process Development:** We offer tailored solutions for the design and optimization of ADC production processes, ensuring high yield and purity. 2. **Analytical Development:** Our state-of-the-art analytical capabilities allow us to perform rigorous characterization and quality control of ADCs, ensuring compliance with regulatory standards. 3. **Clinical Manufacturing:** With robust facilities and scalable production capabilities, we provide cGMP-compliant manufacturing of ADCs for clinical trial supplies ranging from early-phase to large-scale production. 4. **Formulation Development:** Our dedicated team develops optimized formulations for ADC delivery, enhancing stability and therapeutic efficacy. 5. **Regulatory Support:** We guide our clients through the complex regulatory landscape, offering experienced support for IND submissions, CMC documentation, and interactions with regulatory agencies. At [Your Company Name], we pride ourselves on our collaborative approach, working closely with our clients to understand their unique needs and provide solutions that drive their success in the market. With a strong focus on innovation, quality, and timeline management, we are your trusted partner for ADC CDMO Services. Discover how [Your Company Name] can help you bring your ADC products to life and make a meaningful impact in the fight against cancer. Contact us today to learn more about our services and how we can assist you in achieving your goals.

We can offer a full range of chemistry related services covering all phases of your drug discovery project and provide high quality compounds from mgs to kgs. Customers can cooperate with us on a Fee for Service (FFS) or Full Time Equivalent (FTE) basis. Different collaboration models are available for customers choices.

Essential Amino Acid, Histidine, Isoleucine, Leucine, Glutamic Acid, Glycine, Proline, Taurin, Phenylalanine, Tyrosine, Cystine, Threonine, Tryptophan, Calcium, Phosphorous, Iron, Copper, Zinc, Iodine, L-carnitine Indications This Multivitamin chewable Tablet provides a variety of trace elements required for the growth and metabolism of dogs and cats, helps maintain normal physiological functions, and is used for malnutrition, growth retardation, pica, poor hair color, dander and other adverse manifestations caused by the lack of trace elements. It is suitable for dogs and cats at all ages, such as growth period/pregnancy lactation/adult/old age, which can supplement nutrition and increase the protection of dogs and cats.

Specification: 25mg 44mg 75mg 100mg Main ingredient:  Carprofen 25mg/44mg/75mg/100mg Indications:  Used to relieve pain and inflammation caused by bone and joint in dogs and cats, and to relieve pain after soft tissue and bone surgery Target:  Dogs and cats over 6 weeks of age Usage and dosage:  Orally, once a day, 4.4mg per 1kg body weight for dogs and cats; Or 2 times a day, every 1kg of body weight, dogs and cats are fed 2.2mg.

Oclacitinib Maleate Appearance This product is a light brown or brown, cross-scored tablet. Dosage and Administration Calculated as oclacitinib. Oral administration: For dogs, 0.4 ～ 0.6 mg per 1 kg of body weight, twice a day for 14 consecutive days, and then once a day for maintenance therapy. Oclacitinib is a synthetic intracellular non-receptor tyrosine kinase (Janus kinase, JAK for short) inhibitor. It inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.

Viclaner chewable tablets Can be used for breeding dogs, pregnant and lactating female dogs. Fluralaner has a high plasma protein binding rate and may compete with other drugs with a high protein binding rate, such as non-steroidal anti- inflammatory drugs, coumarin derivative warfarin, etc. In vitro plasma incubation tests, there was no evidence of competitive plasma protein binding between fluralaner and carprofen and warfarin. The clinical trials did not find any interaction between fluralaner and the daily medication used in dogs. In case of any serious reactions or other adverse reactions not mentioned in this manual, please consult a veterinarian in time.

Main Ingredients Imidacloprid, Moxidectin Character This product is yellow to brownish yellow liquid. Indications The Imidacloprid and Moxidectin Spot-on Solutions is indicated for the prevention and treatment of internal and external parasitic infections in dogs. The product is indicated for the prevention and treatment of flea infections (Ctenocephalus felis), treatment of lice infections (Trichodelus Canis), treatment of ear mite infections (Pruritus auriculu), canine scabies (Sarcoptes scabies) and demodicidosis (Demodex Canis), treatment of vascular and gastrointestinal nematode infections (adults, immature adults and L4 stage larvae of Toxocephalus Canis, Canis Haemostoma and Ancylostoma Canis); Adult Toxocaris lionis and Trichocephalus vulgaris), prevention of cardiac filariasis (stage L3 and L4 larvae of Difilaria Canis), treatment of circulating microfilariae (Difilaria Canis). And can assist in the treatment of allergic dermatitis caused by fleas.